Clinical Research Directory

Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)

Sponsor: European EGPA Study Group

Summary

This observational study aims to evaluate the long-term effectiveness and safety of mepolizumab 300 mg/4 weeks in adults with eosinophilic granulomatosis with polyangiitis (EGPA) in the European real-life setting. The main questions it aims to answer are: * How effective is mepolizumab 300 mg/4 weeks over long-term follow-up in patients with EGPA? * How safe is mepolizumab 300 mg/4 weeks during long-term treatment? * What are the effects of switching mepolizumab dosage from 300 mg/4 weeks to 100 mg/4 weeks, or from 100 mg/4 weeks to 300 mg/4 weeks? Participants already receiving mepolizumab as part of routine clinical practice. Researchers will retrospectively collect demographic, clinical, laboratory, and treatment-related data from medical records. For patients starting mepolizumab 300 mg/4 weeks, data will be collected from treatment initiation and during follow-up up to 60 months. For patients who change mepolizumab dose, data will also be collected at the time of dose switch and 3 months later.

Official title: Assessing The Long-Term Effectiveness and Safety of Mepolizumab 300mg/Month in the European Real-Life Setting (Mepo Long-term Study)

Key Details

Conditions

Interventions

Locations (1)